Skip to main content
SpringerLink
Log in

Nicotine Replacement Therapy

  • Reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 23 Accesses

Abstract

Tobacco smoking with its long history is of still high prevalence worldwide and has a high impact on human health and an enormous economic burden due to its toxicity and its high addictive potential. One obvious possibility of treatment is a suited way of nicotine substitution and then tapering off. Different products of replacement therapy that deliver nicotine via an oral, transdermal, or pulmonal way are applied for smoking cessation and relapse prevention, whenever possible and only to reduce smoking behavior as a means of harm reduction if complete abstinence is not achieved. The efficacy of NRT, even if challenged by diverse studies, could be shown in numerous RCTs, meta-analyses, and Cochrane reviews including recent ones. Genetic studies and combination therapies might provide new opportunities for differential approaches of NRT to augment its efficacy. In groups of certain risk such as minors or pregnant woman, NRT can be applied in single cases if psychosocial measures failed because side effects are rare. In conclusion, still nowadays with increasing therapeutic possibilities like noradrenaline-dopamine-reuptake inhibitors, nicotine receptor partial agonists, or vaccination trials, NRT is an easy, well-tolerated, and cost-effective way that guidelines still recommend as a first step besides counselling in smoking cessation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Addicott MA. Tobacco addiction: cognition, reinforcement, and mood. In: Verdejo-Garcia A, editor. Cognition and addiction. Amsterdam: Elsevier; 2020. p. 129–41.

    Google Scholar 

  • Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105:1362–80.

    PubMed  Google Scholar 

  • Akanbi MO, Carroll AJ, Achenbach C, O’Dwyer LC, Jordan N, Hitsman B, Bilaver LA, McHugh MC, Murphy R. The efficacy of smoking cessation interventions in low- and middle-income countries: a systematic review and meta-analysis. Addiction. 2019;114:620–35.

    PubMed  PubMed Central  Google Scholar 

  • Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89:73–120.

    CAS  PubMed  Google Scholar 

  • Allenby CE, Boylan KA, Lerman C, Falcone M. Precision medicine for tobacco dependence: development and validation of the nicotine metabolite ratio. J Neuroimmune Pharmacol. 2016;11:471–83.

    PubMed  PubMed Central  Google Scholar 

  • Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob Control. 2013;22:32–7.

    PubMed  Google Scholar 

  • Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav. 2011;36:764–8.

    PubMed  PubMed Central  Google Scholar 

  • Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Gong J, Williams KE, Reeves KR. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63:717–24.

    PubMed  Google Scholar 

  • Aumann I, Rozanski K, Damm K, Graf von der Schulenburg JM. Cost-effectiveness of pharmacological smoking cessation therapies – a systematic literature review. Gesundheitswesen. 2016;78:660–1.

    CAS  PubMed  Google Scholar 

  • Balfour DJK, Munafò MR. Chapter 9. The neurobiology and genetics of nicotine and tobacco. Cham/Heidelberg/New York: Springer; 2015.

    Google Scholar 

  • Batra A. Therapie der Tabakabhängigkeit. Dtsch Aerztebl. 2011;108:555–64.

    Google Scholar 

  • Batra A, Leidinger P. Tabakabhängigkeit. In: Deutsche Hauptstelle für Suchtfragen e.V., editor. Suchtmedizinische Reihe. Vol. 2. Hamm: Deutsche Hauptstelle für Suchtfragen e.V., 2013.

    Google Scholar 

  • Belluzzi JD, Wang R, Leslie FM. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology. 2005;30:705–12.

    CAS  PubMed  Google Scholar 

  • Benkert O, Hippius H. Lehrbuch der Psychiatrischen Pharmakotherapie. 12th ed. Berlin: Springer; 2019.

    Google Scholar 

  • Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bundesamt (Destatis). Rauchgewohnheiten nach Altersgruppen und Geschlecht. Wiesbaden: Bundesamt (Destatis); 2020.

    Google Scholar 

  • Burgis E. Allgemeine und spezielle Pharmakologie. München/Jena: Urban & Fischer; 2000.

    Google Scholar 

  • Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.

    Google Scholar 

  • Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;5:CD006103.

    Google Scholar 

  • CDC. Racial/ethnic disparities and geographic differences in lung cancer incidence – 38 states and the District of Columbia, 1998–2006. MMWR Morb Mortal Wkly Rep. 2010;59:1434–8.

    Google Scholar 

  • Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015;15:689.

    PubMed  PubMed Central  Google Scholar 

  • Chen LS, Baker TB, Jorenby D, Piper M, Saccone N, Johnson E, Breslau N, Hatsukami D, Carney RM, Bierut LJ. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend. 2015;154:278–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chiba M, Masironi R. Toxic and trace elements in tobacco and tobacco smoke. Bull World Health Organ. 1992;70:269–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Choi HD, Shin WG. Association between catechol-O-methyltransferase (COMT) Val/Met genotype and smoking cessation treatment with nicotine: a meta-analysis. Pharmacogenomics. 2015;16:1879–85.

    CAS  PubMed  Google Scholar 

  • Clarke PB, Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 1985;348:355–8.

    CAS  PubMed  Google Scholar 

  • Coleman T, Chamberlain C, Cooper S, Leonardi-Bee J. Efficacy and safety of nicotine replacement therapy for smoking cessation in pregnancy: systematic review and meta-analysis. Addiction. 2011;106:52–61.

    PubMed  Google Scholar 

  • Coleman T, Cooper S, Thornton JG, Grainge MJ, Watts K, Britton J, Lewis S. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med. 2012;366:808–18.

    CAS  PubMed  Google Scholar 

  • Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM, Bernath A, Loots ML, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007;82:186–95.

    CAS  PubMed  Google Scholar 

  • Crooks PA, Bardo MT, Dwoskin LP. Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol. 2014;69:513–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170:324–33.

    PubMed  Google Scholar 

  • Dale Horst W, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treat. 2005;1:349–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dekant W, Vamvakas S. Tobacco. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017. p. 998–1003.

    Google Scholar 

  • Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years observation on male British doctors. BMJ. 2004;328:1519–28.

    PubMed  PubMed Central  Google Scholar 

  • Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, Nides MA, Ascher JA, Johnston JA. Impact of prior nicotine replacement therapy on smoking cessation efficacy. Am J Health Behav. 2002;26:213–20.

    PubMed  Google Scholar 

  • Ebbert J, Montori VM, Erwin PJ, Stead LF. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev. 2011;2:CD004306.

    Google Scholar 

  • Eichelbaum M, Schwab M. Wirkungen des Organismus auf Pharmaka: allgemeine Pharmakokinetik. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017. p. 41.

    Google Scholar 

  • Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, Gervais A, O’Loughlin J, Paradis G, Rinfret S, Pilote L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179:135–44.

    PubMed  PubMed Central  Google Scholar 

  • Ekpu VU, Brown AK. The economic impact of smoking and of reducing smoking prevalence: review of evidence. Tob Use Insights. 2015;8:1–35.

    PubMed  PubMed Central  Google Scholar 

  • Eriksen M, Mackay J, Schluger N, Gomeshtapeh F, Drope J. The tobacco atlas. Atlanta: American Cancer Society; 2015. p. 87.

    Google Scholar 

  • Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control. 2006;15:280–5.

    PubMed  PubMed Central  Google Scholar 

  • Etter JF, Huguelet P, Perneger TV, Cornuz J. Nicotine gum treatment before smoking cessation: a randomized trial. Arch Intern Med. 2009;169:1028–34.

    PubMed  Google Scholar 

  • European Network for Smoking and Tobacco Prevention (ENSP). European smoking cessation guidelines: the authoritative guide to a comprehensive understanding of the implications and implementation of treatments and strategies to treat tobacco dependence. Brüssel: ENSP; 2012.

    Google Scholar 

  • Fagerstrom K, Rutqvist LE, Hughes JR. Snus as a smoking cessation aid: a randomized placebo-controlled trial. Nicotine Tob Res. 2011;14:306–12.

    PubMed  Google Scholar 

  • Fanshawe TR, Hartmann-Boyce J, Perera R, Lindson N. Competitions for smoking cessation. Cochrane Database Syst Rev. 2019;2:CD013272.

    PubMed  Google Scholar 

  • Filbey FM. The neuroscience of addiction. Cambridge/New York: Cambridge University Press; 2019. p. 1–63.

    Google Scholar 

  • Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz N, Curry SJ. Treating tobacco use and dependence: 2008 update. US Public Health Service Clinical Practice guideline executive summary. Respir Care. 2008;53:1217–22.

    Google Scholar 

  • Garduño J, Galindo-Charles L, Jiménez-Rodríguez J, Galarraga E, Tapia D, Mihailescu S, Hernandez-Lopez S. Presynaptic α4β2 nicotinic acetylcholine receptors increase glutamate release and serotonin neuron excitability in the dorsal raphe nucleus. J Neurosci. 2012;32:15148–57.

    PubMed  PubMed Central  Google Scholar 

  • Global Burden of Disease Study Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015. A systematic analysis from the global burden of disease study 2015. Lancet. 2017;389:1885–906.

    Google Scholar 

  • Gourlay SG, Stead LF, Benowitz N. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;3:CD000058.

    Google Scholar 

  • Gowing LR, Ali RL, Allsop S, Marsden J, Turf EE, West R, Witton J. Global statistics on addictive behaviours: 2014 status report. Addiction. 2015;110:904–19.

    PubMed  Google Scholar 

  • Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, Marks MJ. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol. 2007;74:1235–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Greenbaum L, Lerer B. Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions. Mol Psychiatry. 2009;14:912–945.

    Google Scholar 

  • Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. 2013;8:CD003999.

    Google Scholar 

  • Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014;109:1414–25.

    PubMed  Google Scholar 

  • Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5:CD000146.

    PubMed  Google Scholar 

  • Hecht SS, Carmella SG, Murphy SE, Riley WT, Le C, Luo X, Mooney M, Hatsukami DK. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Biomark Prev. 2007;16:1567–72.

    CAS  Google Scholar 

  • Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55:281–99.

    PubMed  Google Scholar 

  • Hiller K, Melzig MF. Lexikon der Arzneipflanzen und Drogen. Part II. Heidelberg: Spektrum Akademischer Verlag; 2000. p. 97.

    Google Scholar 

  • Hitsman B, Hogarth L, Tseng LJ, Teige JC, Shadel WG, DiBenedetti DB, Danto S, Lee TC, Price LH, Niaura R. Dissociable effect of acute varenicline on tonic versus cue-provoked craving in non-motivated heavy smokers. Drug Alcohol Depend. 2013;130:135–41.

    CAS  PubMed  Google Scholar 

  • Hoffmeister D. Chapter 35. Giftpflanzen, Pflanzengifte. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017. p. 1020f.

    Google Scholar 

  • Hofmann F. Chapter 1. Wirkungen von Pharmaka auf den Organismus: allgemeine Pharmakodynamik. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017. p. 4.

    Google Scholar 

  • Hogarth L, Chase HW. Evaluating psychosocial markers for human nicotine dependence: tobacco choice, extinction, and Pavlovian-to-instrumental transfer. Exp Clin Psychopharmacol. 2012;20:213–24.

    PubMed  Google Scholar 

  • Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29–38.

    PubMed  Google Scholar 

  • Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res. 2005;7:491–9.

    CAS  PubMed  Google Scholar 

  • Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;1:CD000031.

    Google Scholar 

  • Hughes JR, Fanshawe TR, Stead LF. Is nicotine replacement really ineffective? A reply to Stanley and Massey. J Clin Epidemiol. 2017;81:143–4.

    PubMed  Google Scholar 

  • IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions. Lyon: International Agency for Research on Cancer; 2012.

    Google Scholar 

  • Improgo MR, Scofield MD, Tapper AR, Gardner PD. The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer. Prog Neurobiol. 2010;92:212–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Itier V, Bertrand D. Neuronal nicotinic receptors: from protein structure to function. FEBS Lett. 2001;504:118–25.

    CAS  PubMed  Google Scholar 

  • Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med. 2014;370:60–8.

    CAS  PubMed  Google Scholar 

  • Jödick B, Neubert D. Reproduktion und Entwicklung. In: Marquardt H, Schäfer S, editors. Lehrbuch der Toxikologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2004. p. 521.

    Google Scholar 

  • Johnson MW, Bickel WK. The behavioral economics of cigarette smoking: the concurrent presence of a substitute and an independent reinforcer. Behav Pharmacol. 2003;14:137–44.

    CAS  PubMed  Google Scholar 

  • Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. 1999;22:555–61.

    CAS  PubMed  Google Scholar 

  • Kaina B. Chemische Karzinogenese. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017a. p. 936.

    Google Scholar 

  • Kaina B. Chemische Karzinogenese. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017b. p. 947.

    Google Scholar 

  • Kamens HM, Corley RP, Richmond PA, Darlington TM, Dowell R, Hopfer CJ, Stallings MC, Hewitt JK, Brown SA, Ehringer MA. Evidence for association between low frequency variants in CHRNA6/CHRNB3 and antisocial drug dependence. Behav Genet. 2016;46:693–704.

    PubMed  PubMed Central  Google Scholar 

  • Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol. 1997;5:137–42.

    CAS  PubMed  Google Scholar 

  • Kishioka S, Kiguchi N, Kobayashi Y, Saika F. Nicotine effects and the endogenous opioid system. J Pharmacol Sci. 2014;125:117–124.

    Google Scholar 

  • Klemperer EM, Lindson N. Neither NRT aided gradual cessation nor abrupt cessation is superior in producing long-term abstinence: reconciling conflicting results from two recent meta-analyses. Tob Induc Dis. 2019;17:81–2.

    PubMed  PubMed Central  Google Scholar 

  • Kojda G. Pharmakologie/Toxikologie systematisch. 2nd ed. Bremen: UNI-ME; 2002.

    Google Scholar 

  • Kralikova E, Kozak JT, Rasmussen T, Gustavsson G, Le Houezec J. Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler. BMC Public Health. 2009;9:433.

    PubMed  PubMed Central  Google Scholar 

  • La Torre G, Grassi MC. Basic principles of smoking cessation techniques. In: La Torre G, editor. Smoking prevention and cessation. New York/Heidelberg/Dordrecht/London: Springer; 2013. p. 254.

    Google Scholar 

  • Lampert T. Verbreitung des Rauchens in der Erwachsenenbevölkerung in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013;56:802–8.

    CAS  Google Scholar 

  • Lampert T, Kuntz B. Tabak- und Alkoholkonsum bei 11- bis 17-jährigen Jugendlichen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2014;57:830–9.

    CAS  Google Scholar 

  • Lancaster T, Hajek P, Stead LF, West R, Jarvis MJ. Prevention of relapse after quitting smoking: a systematic review of trials. Arch Intern Med. 2006;166:828–835.

    Google Scholar 

  • Laniado-Laborín R. Smoking cessation intervention: an evidence-based approach. Postgrad Med. 2010;122:74–82.

    PubMed  Google Scholar 

  • Lee PN, Fariss MW. A systematic review of possible serious adverse health effects of nicotine replacement therapy. Arch Toxicol. 2017;91:1565–94.

    CAS  PubMed  Google Scholar 

  • Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, Tyndale RF, Group P-PR. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3:131–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Leung T, Bergen A, Munafo MR, De Ruyck K, Selby P, De Luca V. Effect of the rs1051730–rs16969968 variant and smoking cessation treatment: a meta-analysis. Pharmacogenomics. 2015;16:713–20.

    CAS  PubMed  Google Scholar 

  • Levin ED. α7-Nicotinic receptors and cognition. Curr Drug Targets. 2012;13:602–6.

    CAS  PubMed  Google Scholar 

  • Leweke FM, Koethe D. Psychopharmaka – Pharmakotherapie psychischer Erkrankungen. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017. p. 300.

    Google Scholar 

  • Li MD. Tobacco smoking addiction: epidemiology, genetics, mechanisms, and treatment. Singapore: Springer Nature; 2018.

    Google Scholar 

  • Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019a;4:CD013308.

    PubMed  Google Scholar 

  • Lindson N, Klemperer E, Hong B, Ordóñez-Mena JM, Aveyard P. Smoking reduction interventions for smoking cessation. Cochrane Database Syst Rev. 2019b;9:CD013183.

    PubMed  Google Scholar 

  • Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, Hajek P. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. 2019;10:CD003999.

    Google Scholar 

  • MacKenzie R, Rogers W. New insights into smoking cessation question the effectiveness of nicotine replacement therapy. J Clin Epidemiol. 2016;79:168–9.

    PubMed  PubMed Central  Google Scholar 

  • Malenka RC, Nestler EJ, Hyman SE. Autonomic Nervous System. In: Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical; 2009, p. 234

    Google Scholar 

  • Mann K, Batra A, Hoch E, Leitliniengruppe D. S3-Leitlinie “Screening, Diagnose und Behandlung alkoholbezogener Störungen”. Sucht. 2017;63:7–23.

    Google Scholar 

  • McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M, Whittaker R, Hajek P. A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction. Addiction. 2010;105:1290–8.

    PubMed  Google Scholar 

  • Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature. 2003;423:949–55.

    CAS  PubMed  Google Scholar 

  • Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, Schroeder JR. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics. 2005;115:407–14.

    Google Scholar 

  • Mutschler E, Geisslinger G, Kroemer HK, Ruth P, Schäfer-Korting M. Arzneimittelwirkungen. 9th ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2008.

    Google Scholar 

  • NICE (National Institute for Health and Care Excellence). Stop smoking interventions and services. NICE guideline [NG92]. www.nice.org.uk/guidance/ng92 (2018). Published Mar 2018.

  • Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047–53.

    PubMed  Google Scholar 

  • Ollrogge I. Grenzwerte, Richtwerte, Empfehlungen. In: Marquardt H, Schäfer S, editors. Lehrbuch der Toxikologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2004a. p. 1275.

    Google Scholar 

  • Ollrogge I. Grenzwerte, Richtwerte, Empfehlungen. In: Marquardt H, Schäfer S, editors. Lehrbuch der Toxikologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2004b. p. 1291.

    Google Scholar 

  • Pentel PR, LeSage MG. New directions in nicotine vaccine design and use. Adv Pharmacol. 2014;69:553–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76:116–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Pitchford S, Day JW, Gordon A, Mochly-Rosen D. Nicotinic acetylcholine receptor desensitization is regulated by activation-induced extracellular adenosine accumulation. J Neurosci. 1992;12:4540–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996;382:255–7.

    CAS  PubMed  Google Scholar 

  • Prescrire. Cardiac adverse effects of nicotine replacement therapy. Prescrire Int. 2015;24:292–3.

    Google Scholar 

  • Richter E, Scherer G. Aktives und passives Rauchen. In: Marquardt H, Schäfer S, editors. Lehrbuch der Toxikologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2004. p. 897–918.

    Google Scholar 

  • Ritter J, Flower R, Henderson G, Loke YK, MacEwan D, Rang H. Rang and Dale’s pharmacology. 9th ed. Amsterdam: Elsevier; 2019.

    Google Scholar 

  • Rose JE, Corrigall WA. Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology. 1997;130:28–40.

    CAS  PubMed  Google Scholar 

  • Rubinstein ML, Benowitz NL, Auerback GM, Moscicki AB. A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics. 2008;122:e595–600.

    PubMed  Google Scholar 

  • Ruether T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, Gorwood P, Moeller HJ. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry. 2014;29:65–82.

    Google Scholar 

  • Rupprecht LE, Smith TT, Schassburger RL, Buffalari DM, Sved AF, Donny EC. Behavioral mechanisms underlying nicotine reinforcement. In: Balfour DJK, Munafò MR, editors. The pharmacology of nicotine dependence. Cham/Heidelberg/New York: Springer; 2015.

    Google Scholar 

  • Sarter M. Behavioral-cognitive targets for cholinergic enhancement. Curr Opin Behav Sci. 2015;4:22–6.

    PubMed  PubMed Central  Google Scholar 

  • Schubert R. Arzneiformen. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017. p. 72.

    Google Scholar 

  • Schuit E, Panagiotou OA, Munafò MR, Bennett DA, Bergen AW, David SP. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. Cochrane Database Syst Rev. 2017;9:CD011823.

    PubMed  Google Scholar 

  • Solecki R, Pfeil R. Biozide und Pflanzenschutzmittel. In: Marquardt H, Schäfer S, editors. Lehrbuch der Toxikologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2004. p. 682.

    Google Scholar 

  • Squire L. Fundamental neuroscience. 2nd ed. Amsterdam: Academic Press; 2003. p. 1426.

    Google Scholar 

  • Stanley TD. Considerations of statistical power and risk of bias question the strength of nicotine replacement therapy’s effectiveness. J Clin Epidemiol. 2016;79:169–70.

    CAS  PubMed  Google Scholar 

  • Stanley TD. Yes, nicotine replacement therapy’s effectiveness is much lower than often reported. J Clin Epidemiol. 2017;81:144–5.

    CAS  PubMed  Google Scholar 

  • Starke K. Chapter 3. Pharmakologie cholinerger Systeme. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017a. p. 127f.

    Google Scholar 

  • Starke K. Chapter 3. Pharmakologie cholinerger Systeme. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017b. p. 113.

    Google Scholar 

  • Starke K. Chapter 4. Pharmakologie noradrenerger und adrenerger Systeme. In: Aktories K, Förstermann U, Hofmann FB, Starke K, editors. Allgemeine und spezielle Pharmakologie und Toxikologie. 12th ed. München: Elsevier; 2017c. p. 139.

    Google Scholar 

  • Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2007;3:CD005231.

    Google Scholar 

  • Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012a;10:CD008286.

    PubMed  Google Scholar 

  • Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2012b;12:CD009670.

    PubMed  Google Scholar 

  • Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;1:CD000146.

    Google Scholar 

  • Steinlein OK, Bertrand D. Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases. Biochem Pharmacol. 2008;76:1175–1183.

    Google Scholar 

  • Tan J, Zhao L, Chen H. A meta-analysis of the effectiveness of gradual versus abrupt smoking cessation. Tob Induc Dis. 2019. https://doi.org/10.18332/tid/100557.

  • Tonnesen P, Mikkelsen K, Bremann L. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial. Nicotine Tob Res. 2008;10:1365–72.

    PubMed  Google Scholar 

  • Tonstad S, Gustavsson G, Kruse E, Walmsley JM, Westin A. Symptoms of nicotine toxicity in subjects achieving high cotinine levels during nicotine replacement therapy. Nicotine Tob Res. 2014;16:1266–71.

    CAS  PubMed  Google Scholar 

  • Torchalla I, Okoli CT, Bottorff JL, Qu A, Poole N, Greaves L. Smoking cessation programs targeted to women: a systematic review. Women Health. 2012;52:32–54.

    PubMed  Google Scholar 

  • Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;2:CD007253.

    Google Scholar 

  • Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, Swan GE, Benowitz NL, Heitjan DF, Lerman C, Group P-PR. Lack of associations of CHRNA5-A3-B4 genetic variants with smoking cessation treatment outcomes in Caucasian smokers despite associations with baseline smoking. PLoS One. 2015;10:e0128109.

    PubMed  PubMed Central  Google Scholar 

  • Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol. 2005;346:967–89.

    CAS  PubMed  Google Scholar 

  • Villégier AS, Salomon L, Granon S, Changeux JP, Belluzzi JD, Leslie FM, Tassin JP. Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine. Neuropsychopharmacology. 2006;31:1704–13.

    PubMed  Google Scholar 

  • Weinberger AH, Smith PH, Kaufman M, McKee SA. Consideration of sex in clinical trials of transdermal nicotine patch: a systematic review. Exp Clin Psychopharmacol. 2014;22:373–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  • West R. Tobacco smoking: health impact, prevalence, correlates and interventions. Psychol Health. 2017;32:1018–36.

    PubMed  PubMed Central  Google Scholar 

  • Westendorf J. Naturstoffe. In: Marquardt H, Schäfer S, editors. Lehrbuch der Toxikologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2004. p. 1070.

    Google Scholar 

  • WHO. Global health risks. Mortality and burden of disease attributable to selected major risks. Geneva: WHO; 2009.

    Google Scholar 

  • WHO. WHO report on the global tobacco epidemic, 2013: enforcing bans on tobacco advertising, promotion and sponsorship. Geneva: WHO; 2013.

    Google Scholar 

  • Windle SB, Filion KB, Mancini JG, Adye-White L, Joseph L, Gore GC, Habib B, Grad R, Pilote L, Eisenberg MJ. Combination therapies for smoking cessation: a hierarchical Bayesian meta-analysis. Am J Prev Med. 2016;51:1060–71.

    PubMed  Google Scholar 

  • Wise RA. Dopamine, learning, and motivation. Nat Rev Neurosci. 2004;5:483–94.

    CAS  PubMed  Google Scholar 

  • Wu J, Gao M, Shen JX, Shi WX, Oster AM, Gutkin BS. Cortical control of VTA function and influence on nicotine reward. Biochem Pharmacol. 2013;86:1173–80.

    CAS  PubMed  Google Scholar 

  • Yamamoto I, Casida JE. Nicotinoid insecticides and the nicotinic acetylcholine receptor. Singapore: Springer; 1999.

    Google Scholar 

  • Zbikowski SM, Magnusson B, Pockey JR, Tindle HA, Weaver KE. A review of smoking cessation interventions for smokers aged 50 and older. Maturitas. 2012;71:131–41.

    PubMed  Google Scholar 

  • Zhang T, Zhang L, Liang Y, Siapas AG, Zhou FM, Dani JA. Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J Neurosci. 2009;29:4035–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zolk O, Eschenhagen T. Kardiotoxizität. In: Marquardt H, Schäfer S, editors. Lehrbuch der Toxikologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2004. p. 563.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Psychosomatics and Psychotherapy, University Clinic Würzburg, Würzburg, Germany

    Thomas Polak

  2. Clinic for Psychiatry and Psychotherapy, medius KLINIK Kirchheim, Kirchheim unter Teck, Germany

    Christian C. Jacob

Authors
  1. Thomas Polak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian C. Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Polak .

Editor information

Editors and Affiliations

  1. Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Wuerzburg, Germany

    Peter Riederer

  2. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  3. Centre for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Germany

    Christian Riederer

Section Editor information

  1. The International College of Neuropsychopharmacology, East Kilbride, Scotland, UK

    Toshikazu Saito

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Polak, T., Jacob, C.C. (2022). Nicotine Replacement Therapy. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_398

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62059-2_398

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62058-5

  • Online ISBN: 978-3-030-62059-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation